p19ras interacts with and activates p73 by involving the MDM2 protein

被引:26
作者
Jeong, MH
Bae, J
Kim, WH
Yoo, SM
Kim, JW
Song, PI
Choi, KH [1 ]
机构
[1] Chung Ang Univ, Coll Nat Sci, Dept Biol Sci, Mol Biol Lab, Seoul 156756, South Korea
[2] Pochon CHA Univ, Grad Sch Life Sci & Biotechnol, Lab Mol Om Therapy, Seongnam 463836, South Korea
[3] Norean Natl Inst Hlth, Korea Ctr Dis Control & Prevent, Seoul 122701, South Korea
[4] Univ Colorado, Hlth Sci Ctr, Dept Dermatol, Aurora, CO 80045 USA
关键词
D O I
10.1074/jbc.M513853200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
p73 beta is a structural and functional homologue of p53, a tumor suppressor gene. In this study, we identified a novel p73 beta-binding protein, p19(ras), by the yeast two-hybrid screening method. Alternative splicing of the proto-oncogene H-ras pre-mRNA has led to two distinct transcripts, p19(ras) and p21(ras). In both endogenous and overexpressed systems, we confirmed that p19(ras) binds to full-length p73 beta in vivo and in vitro. Coexpression of p19(ras) with p73 beta stimulated the transcriptional activity of p73 beta. Ras proteins are known to be small membrane-localized guanine nucleotide-binding proteins. However, unlike other Ras proteins, p19(ras) is localized in the nucleus and the cytosol and its interaction with p73 beta occurred exclusively in the nucleus. Oncogenic MDM2 ( mouse double minutes 2) is a known repressor of p73 transcriptional activity. In this study, when p19(ras) was bound to MDM2, it further inhibited the association of MDM2 to the p73 beta protein. In addition, p19(ras) abolished MDM2-mediated transcriptional repression of p73 beta. Therefore, this study presents a novel pathway of Ras signaling that occurs in the nucleus, involving p19(ras) and p73 beta. Furthermore, a p19(ras)-mediated novel regulatory mechanism of p73 involving the MDM2 protein is described.
引用
收藏
页码:8707 / 8715
页数:9
相关论文
共 47 条
[1]  
Agami R, 1999, NATURE, V399, P809
[2]   Physical and functional interaction between HCV core protein and the different p73 isoforms [J].
Alisi, A ;
Giambartolomei, S ;
Cupelli, F ;
Merlo, P ;
Fontemaggi, G ;
Spaziani, A ;
Balsano, C .
ONCOGENE, 2003, 22 (17) :2573-2580
[3]   Mdm2 binds p73α without targeting degradation [J].
Bálint, E ;
Bates, S ;
Vousden, KH .
ONCOGENE, 1999, 18 (27) :3923-3929
[4]   ASPP1 and ASPP2: Common activators of p53 family members [J].
Bergamaschi, D ;
Samuels, Y ;
Jin, BQ ;
Duraisingham, S ;
Crook, T ;
Lu, X .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (03) :1341-1350
[5]   The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63 [J].
Calabrò, V ;
Mansueto, G ;
Parisi, T ;
Vivo, M ;
Calogero, RA ;
La Mantia, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (04) :2674-2681
[6]  
CHEN CY, 1995, ONCOGENE, V11, P1487
[7]   EXPRESSION OF THE H-RAS PROTO-ONCOGENE IS CONTROLLED BY ALTERNATIVE SPLICING [J].
COHEN, JB ;
BROZ, SD ;
LEVINSON, AD .
CELL, 1989, 58 (03) :461-472
[8]   Ras signalling and apoptosis [J].
Downward, J .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (01) :49-54
[9]   CONSTITUTIVE EFFECTOR REGION ON THE C-TERMINAL SIDE OF SWITCH-I OF THE RAS PROTEIN [J].
FUJITAYOSHIGAKI, J ;
SHIROUZU, M ;
ITO, Y ;
HATTORI, S ;
FURUYAMA, S ;
NISHIMURA, S ;
YOKOYAMA, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (09) :4661-4667
[10]  
Guil S, 2003, CANCER RES, V63, P5178